Liraglutide’s use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver related morbidity and mortality and also is the second most common cause of liver transplantation in the United States (1).